Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

To describe the safety of this vaccine following first and second dose immunization.

To assess preliminary information of immunogenicity following Vi-DT vaccine immunization.

Inclusion criteria

• Healthy
• Subjects/Parents have been informed properly regarding the study and signed the informed consent form
• Subject/Parents will commit to comply with the instructions of the investigator and the schedule of the trial

Exclusion criteria

• Subject concomitantly enrolled or scheduled to be enrolled in another trial
• Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C )
• Known history of allergy to any component of the vaccines
• History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection
• Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks).
• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives
• Pregnancy & lactation (Adults)
• Individuals who have previously received any vaccines against typhoid fever.
• Subjects already immunized with any vaccine within 4 weeks prior and expect to receive other vaccines within 60 days following the first dose.
• Individuals who have a previously ascertained typhoid fever.
• History of alcohol or substance abuse.
• Subject planning to move from the study area before the end of study period.